Navigation Links
STAAR Surgical Launches New Visian ICL™ Product Line Extensions at ESCRS
Date:9/8/2010

MONROVIA, Calif., Sept. 8 /PRNewswire/ -- STAAR Surgical Company (Nasdaq: STAA), the leading worldwide developer, manufacturer and marketer of phakic intraocular lenses, today announced that the Visian Implantable Collamer® Lens (ICL) was featured prominently in more than 40 presentations by leading ophthalmologists at meetings prior to and during the 2010 Congress of European Society of Cataract and Refractive Surgeons (ESCRS) held in Paris, France from September 4 through 8, 2010.  The presentations, based on studies conducted by surgeons throughout the world, confirmed that the Visian ICL offers superior visual results over a wide range of myopic and hyperopic refractive errors including those within the most popular LASIK areas of treatment.  These presentations also confirmed the safety and efficacy of the Visian ICL over a period of 17 years.  

The 7th Annual Visian ICL Expert Meeting, sponsored by STAAR, was held prior to the conference with 100 surgeons from 34 countries in attendance.  There were 26 presentations and eight specialized breakout sessions on ICL topics over a two-day period.  During the opening presentation Hans Blickensdoerfer, President of STAAR Europe, Latin America and the Middle East, demonstrated the growth in Visian ICL procedures by comparing the rate of ICL implants per minute.  In 2008, worldwide, a Visian ICL was implanted every 20 minutes; that rate has doubled in 2010 to one implant every 10 minutes.

"This was our seventh annual meeting of this type and I believe it was the best," commented Mr. Blickensdoerfer.  "We continue to see strong growth in the Visian ICL throughout the world and believe that the newly expanded Visian ICL diopter ranges launched here at ESCRS more than doubles the market opportunity for Visian and allow us to compete directly within the most popular myopic and hype
'/>"/>

SOURCE STAAR Surgical Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. STAAR Surgical to Present at the 20th Annual Oppenheimer Healthcare Conference in New York
2. STAAR Surgical Announces Third Quarter 2009 Earnings Release Date and Conference Call
3. STAAR Surgical Generates $464,000 in Cash from Operations During Third Quarter
4. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
5. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
6. Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes
7. New Non-Surgical Stem-Cell Procedure to Relieve Chronic Tendon Problems
8. Ceremeds OSTENE(R) Stops Bone Bleeding Without Added Risk of Surgical Infection, New Study Finds
9. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
10. Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy
11. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... and CAMBRIDGE, Mass., May 28, 2015  Shareholder rights ... whether certain officers and directors of Eleven ... shareholders.  Eleven Biotherapeutics is a clinical-stage biopharmaceutical company ... protein therapeutics to treat eye diseases, primarily in ... View this press release on the ...
(Date:5/28/2015)... , May 27, 2015 The amount Americans ... in 2014 and with growth of 8% will reach ... out of pocket: directly on expenditures, co-pays as part ... and on premiums.  The publisher made its finding in ... the United States . ...
(Date:5/28/2015)... , May 28, 2015 ... Testing Market - Size, Industry Analysis, Trends, Opportunities, Growth and ... reach $3.6 billion by 2020. The secondary syphilis testing ... 2020. Latin America , ... (LAMEA) market accounted for about 43% revenue share ...
Breaking Medicine Technology:Robbins Arroyo LLP Is Investigating the Officers and Directors of Eleven Biotherapeutics, Inc. (EBIO) on Behalf of Shareholders 2Report: U.S. Out-of-Pocket Healthcare Spending Reaches $416 Billion 2Report: U.S. Out-of-Pocket Healthcare Spending Reaches $416 Billion 3Global Syphilis Testing Market is Expected to Reach $3.6 Billion, by 2020 - Allied Market Research 2Global Syphilis Testing Market is Expected to Reach $3.6 Billion, by 2020 - Allied Market Research 3
... Global Sources (Nasdaq: GSOL ) has ... China Sourcing Fairs at Hong ... the renewed contracts announced in June 2010, representing a ... (Logo: http://photos.prnewswire.com/prnh/20030303/LNM011LOGO-b) Under the terms of the ...
... (Nasdaq: AMGN ) today announced the publication ... 1,776 advanced cancer patients with different types of solid ... myeloma, which compared XGEVA ™ (denosumab) to Zometa® ... which appeared today in the Journal of Clinical ...
Cached Medicine Technology:Global Sources extends its contract with AsiaWorld-Expo to host China Sourcing Fairs in Hong Kong through 2014 2Global Sources extends its contract with AsiaWorld-Expo to host China Sourcing Fairs in Hong Kong through 2014 3The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 2The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 3The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 4The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 5The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 6The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 7The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 8
(Date:5/28/2015)... Restricting access to firearms for people ... that more clearly define alcohol misuse should be developed ... research and public policies by the UC Davis Violence ... 30 in the peer-reviewed journal Preventive Medicine , ... alcohol misuse in association with firearm access and use, ...
(Date:5/28/2015)... Scotch Plains, NJ (PRWEB) May 28, 2015 ... Dr. Farhad Rafizadeh, specializes in delivering world-class results. ... of Plastic Surgery and a background in art, Dr. ... look. His unique approach to Plastic Surgery involves ... addition, his practice delivers a superior level of comfort ...
(Date:5/28/2015)... May 28, 2015 Medelis, Inc., a ... joined the company in the role of president. , “ ... in the CRO industry,” said Larry Flanagan, Medelis’ CEO and ... company through our next phase of growth.” , Taaffe ... growth from nine employees to over 4,500 employees, achieving 12 ...
(Date:5/28/2015)... Boston Celtics Legend and Basketball Hall of ... Board of Directors members, will be hosting their 34th ... 4-7. For the past 34 years, the Havlicek’s have ... for children by bringing together friends, families, and celebrities ... Havlicek Celebrity Fishing Tournament will be held from June ...
(Date:5/28/2015)... May 28, 2015 Workers’ compensation costs per ... state, a recent study by the Workers Compensation Research ... a three-year period. , The WCRI study, CompScope™ Benchmarks ... workers missed seven days or more of work with those ... average 2011 Michigan claim was 4 percent lower than similar ...
Breaking Medicine News(10 mins):Health News:UC Davis Research Finds That Restricting Firearms Access for People who Misuse Alcohol May Prevent Violence 2Health News:UC Davis Research Finds That Restricting Firearms Access for People who Misuse Alcohol May Prevent Violence 3Health News:UC Davis Research Finds That Restricting Firearms Access for People who Misuse Alcohol May Prevent Violence 4Health News:"NJ Top Doc", Dr. Farhad Rafizadeh is Excited to Offer New Services at his Plastic Surgery Practice 2Health News:"NJ Top Doc", Dr. Farhad Rafizadeh is Excited to Offer New Services at his Plastic Surgery Practice 3Health News:Bill Taaffe, Former President and CEO of ICON Clinical Research-US, Joins Medelis, a Specialty Oncology CRO, in the Role of President 2Health News:The Genesis Foundation Prepares for Their Final Annual John Havlicek Celebrity Fishing Tournament 2Health News:Michigan Workers’ Compensation Costs Lower Than Most States, Says WCRI Study 2
... that subconjunctivally delivered insulin ameliorates degenerative and inflammatory responses ... Research in Vision and Ophthalmology (ARVO) 2007 Annual Meeting ... on Thursday, May 10 from 10:45 a.m. to 12:30 ... County Convention Center. ,Regular human insulin in ...
... to uncover the medium- and large-scale genetic differences between humans ... wide range of diseases, according to a paper by Howard ... in the May 10, 2007, Nature. The undertaking will help ... amount to as much as five to ten percent of ...
... systems of humans and opossums, the famous Australian marsupial ... in the understanding and treatment of facial tumours afflicting ... the Australian island state of Tasmania. ... genetic information of the South American opossum, the first ...
... two-thirds of US children undergo some trauma or ... them experience post-traumatic stress disorder. ,The ... it also suggests that the way children process troubling ... Duke University Medical Center, whose study appeared in the ...
... at St. Jude Children's Research Hospital had a molecules ... as it assembled on a double-strand break to ... that cut completely across the twisted, ladder-like structure of ... a technique developed specifically for this project, the St. ...
... People infected with the hepatitis C virus (HCV) are ... of the lymphatic system), according to a study ... Journal of the American Medical Association. Researchers from the ... of Health, and Baylor College of Medicine, found that ...
Cached Medicine News:Health News:Cataloging the Structural Variations in Human Genetics 2Health News:Cataloging the Structural Variations in Human Genetics 3Health News:Treatment of Premature Babies, Opossums Could Help 2Health News:Two-thirds of US Children Experience Trauma, but Recover Fast 2Health News:DNA Repair Proteins Monitored at Double-strand Break 2Health News:Risk of Lymphoma Increases With Hepatitis C Virus Infection 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: